Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Rheumatoid Arthritis, Systemic Juvenile 1Rectal Neoplasms 1Periodic Fevers Syndrome 1Neoplasms 1Mevalonate Kinase Deficiency 1Metastatic Pancreatic Ductal Adenocarcinoma 1Melanoma 1Lung Neoplasms 1Intestinal Neoplasms 1Cryopyrin-Associated Periodic Syndromes 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Ductal 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms 1Arthritis, Juvenile 1Arthralgia 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

Fluorouracil 128Leucovorin 120Oxaliplatin 101Irinotecan 89Bevacizumab 55Cetuximab 44Capecitabine 40Folfox protocol 29Panitumumab 22Colonoscopy 17Chemotherapy, Adjuvant 16Floxuridine 15Early Intervention, Educational 15Erlotinib Hydrochloride 13Surveys and Questionnaires 11IFL protocol 11Counseling 11Celecoxib 11Immunohistochemistry 10Gemcitabine 10Psychiatric Rehabilitation 9Methods 8Magnetic Resonance Spectroscopy 8Gene Expression Profiling 8Exercise 8Dexamethasone 8sargramostim 7Sorafenib 7Radiotherapy 7Nivolumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Colonic Neoplasms × canakinumab × Clear all
NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)

Novartis

Phase 1 Completed
283 enrolled
BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔